tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Eric Le Berrigaud, 9 are a HOLD (26.47%), 25 are a BUY (73.53%).
Analyst Eric Le Berrigaud, currently employed at STIFEL, carries an average stock price target met ratio of 42.86% that have a potential upside of 9.72% achieved within 193 days. Previously, Eric Le Berrigaud worked at BRYAN GARNIER.
Eric Le Berrigaud’s has documented 57 price targets and ratings displayed on 8 stocks. The coverage is on Healthcare, Consumer Cyclical sectors.
Most recent stock forecast was given on NVO, Novo Nordisk A/S at 28-Dec-2024.
Analyst best performing recommendations are on NVO (NOVO NORDISK A/S).
The best stock recommendation documented was for NVO (NOVO NORDISK A/S) at 2/28/2022. The price target of $53.34 was fulfilled within 38 days with a profit of $7.44 (16.21%) receiving and performance score of 4.27.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 01-May-2026
$58
4 months 25 days ago
(01-May-2026)
1/9 (11.11%)
$11.2 (23.93%)
224
Buy Since 17-Aug-2023
$50
$8.89 (21.62%)
5 months 3 days ago
(23-Apr-2026)
0/3 (0%)
$4.97 (11.04%)
Hold Since 20-Apr-2026
$143.28
5 months 6 days ago
(20-Apr-2026)
1/3 (33.33%)
$95.69 (201.07%)
3248
Buy Since 30-Oct-2023
8 months 27 days ago
(30-Dec-2025)
0/8 (0%)
$16.47 (41.66%)
Hold Since 31-Jul-2017
$57
$15.89 (38.65%)
$67
9 months ago
(26-Dec-2025)
2/5 (40%)
$11.08 (24.13%)
2160
What Year was the first public recommendation made by Eric Le Berrigaud?
